Prescription medicine
Brimonidine and timolol Brand names: Combigan
Brimonidine and timolol (Combigan) is a prescription medicine with an FDA approval on record since 2007. FDA's NDC Directory lists it from 14 generic labelers, and pharmacies paid $2.15 per mL (Brimonidine-timolol 0.2%-0.5%) in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the brimonidine and timolol FDA label on DailyMed (effective March 17, 2026, Allergan, Inc.); the NDA 21398 record on Drugs@FDA; every brimonidine and timolol label on DailyMed.
Highlights of the record
FDA label of March 17, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageCOMBIGAN ® is indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP.
Forms and strengths
- 2 mg/ml / 5 mg/ml
Solution/ drops; solution.
On the market
- Earliest approval on file
- October 30, 2007 Combigan, Abbvie; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 12 first April 4, 2022; 11 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 15 of which 14 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $2.15 per mL Brimonidine-timolol 0.2%-0.5%
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 5 since 2017 0 Class I among all firms' recalls; latest March 5, 2026
- FAERS reports
- 6,959 through July 30, 2026
What is brimonidine and timolol used for?
From the label: indications and usageCOMBIGAN ® is indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP. The IOP-lowering of COMBIGAN dosed twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol maleate ophthalmic solution dosed twice a day and 0.2% brimonidine tartrate ophthalmic solution dosed three times per day. […]
Conditions named in the indications of brimonidine and timolol's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: alpha-Adrenergic Agonist and beta-Adrenergic Blocker.
Source: FDA drug label (COMBIGAN), NDA021398 (Abbvie), as published by Allergan, Inc., effective March 17, 2026 (SPL set feaf1480-a4b8-4486-992a-96be3a596243), via openFDA; the full label on DailyMed
Is there a generic for brimonidine and timolol (Combigan)?
The FDA approved the first generic brimonidine and timolol on April 4, 2022. 12 generic applications are approved; 11 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale. Drugs@FDA also holds 1 tentative approval: the FDA found the generic approvable, but patents or exclusivity keep it from final approval for now.
FDA's NDC Directory lists brimonidine and timolol from 14 labelers under a generic (ANDA) application and from 1 brand labeler. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 2007 earliest approval on file
- 2022 first generic approved
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for brimonidine and timolol (Combigan)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $2.15 per mL (Brimonidine-timolol 0.2%-0.5%), down 52% from $4.43 on October 8, 2025. The survey records the price, not the reason for a change; large moves often follow a new generic or a list-price change. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Brimonidine-timolol 0.2%-0.5% (generic)
- Combigan 0.2%-0.5% eye drops (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Brimonidine-timolol 0.2%-0.5% | Generic | $2.15 per mL | n/a | -52% |
| Combigan 0.2%-0.5% eye drops | Brand | $39.10 per mL | n/a | -0.2% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has brimonidine and timolol been recalled?
The FDA's Enforcement Report lists 5 recalls naming brimonidine and timolol since 2017: 0 Class I (the most serious), 4 Class II, 1 Class III; 3 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| March 5, 2026 | Class II | Apotex Corp. | Lack of Assurance of Sterility |
| September 5, 2025 | Class II | Apotex Corp. | Lack of Assurance of Sterility; atypical weight loss due to improper bottle sealing leading to potential sterility concerns |
| May 28, 2025 | Class II | Apotex Corp. | Lack of Assurance of Sterility |
| March 19, 2019 | Class II | Allergan Sales, LLC | cGMP Deviations |
| October 19, 2017 | Class III | Allergan Sales, LLC | Failed Impurities/Degradation Specifications. |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the brimonidine and timolol label say about other medicines?
The brimonidine and timolol label names 4 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Benzalkonium | warnings and precautions | Contact Lens Use COMBIGAN contains benzalkonium chloride which may be absorbed by soft contact lenses. |
| Clonidine | drug interactions | … beta-blockade. ( 7.7 ) Tricyclic antidepressants may potentially blunt the hypotensive effect of systemic clonidine. ( 7.8 ) Monoamine oxidase inhibitors may result in increased hypotension. |
| Epinephrine | warnings and precautions | Such patients may be unresponsive to the usual doses of epinephrine used to treat anaphylactic reactions. |
| Quinidine | drug interactions | Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol. |
Source: FDA drug label (COMBIGAN), NDA021398 (Abbvie), as published by Allergan, Inc., effective March 17, 2026 (SPL set feaf1480-a4b8-4486-992a-96be3a596243), via openFDA; the full label on DailyMed
What do FAERS reports show for brimonidine and timolol?
The FDA Adverse Event Reporting System holds 6,959 reports that list brimonidine and timolol among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 326 are coded as a death and 1,086 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as brimonidine and timolol?
14 other medicines are given the same way (ophthalmic) and in the same FDA class as brimonidine and timolol or labeled mainly for the same use (glaucoma), the same class first. Glaucoma lists all 20 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (ophthalmic) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Betaxolol | Glaucoma | none listed | $8.97 per mL 0.5% eye drop | No current entry |
| Carteolol | Glaucoma | 1 labeler | $1.63 per mL 1% eye drops | No current entry |
| Levobunolol | Glaucoma | 1 labeler | $2.82 per mL 0.5% eye drops | No current entry |
| Bimatoprost | Glaucoma | 13 labelers | $6.97 per mL 0.03% eye drops | No current entry |
| Latanoprost | Glaucoma | 14 labelers | $1.58 per mL 0.005% eye drops | No current entry |
| Travoprost | Glaucoma | 11 labelers | $9.07 per mL 0.004% eye drop | A presentation being discontinued |
| Dorzolamide | Glaucoma | 14 labelers | $0.835 per mL 2% eye drops | No current entry |
| Pilocarpine | Glaucoma | 2 labelers | $2.81 per mL 2% eye drops | A presentation being discontinued |
Every medicine labeled for the same conditions as brimonidine and timolol
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to brimonidine and timolol
- 14 medicines for the same use
- Other alpha-adrenergic agonists
- the pharmacologic class, with prices and generics
- Brimonidine and timolol side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other